Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Exec Vice President and CMO | January 03, 2017 | January 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date January 03, 2017 · Filed January 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,368 |
Ending reported balance
After 2017-01-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-01-03 · Exercise / conversion · Acquired 18,055 · Balance 18,055 F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's. Row 2 · 2017-01-04 · Sale · Disposed 6,687 · Balance 11,368 F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 162,501 |
Reported balance
After 2017-01-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-03 · Exercise / conversion · Disposed 18,056 · Balance 162,501 F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's.
F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mineralys Therapeutics, Inc.
Report date August 10, 2026 · Filed August 12, 2026
Section 16 reporting ended · disclosed 2026-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,384 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 2,170 · Balance 53,554 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Row 2 · 2026-08-10 · Sale · Disposed 2,170 · Balance 51,384 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2033-02-09 | Direct | 13,024 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 2,170 · Balance 13,024 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 13, 2026 Filed Jan 16, 2026 00:07 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 7,709 | $32.75 | $252,469.75 |
DisclosureSEC source: 0001672659-26-000006 · wk-form4_1768522053.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,804 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 13, 2026 Filed Jan 16, 2026 00:07 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 4,167 | $14.25 | $59,379.75 |
DisclosureSEC source: 0001672659-26-000006 · wk-form4_1768522053.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 13, 2026 Filed Jan 16, 2026 00:07 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 3,542 | $10.20 | $36,128.40 |
DisclosureSEC source: 0001672659-26-000006 · wk-form4_1768522053.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 01:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001672659-26-000004 · wk-form4_1768355008.xml · derivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,092 Underlying: Common Stock · 6,348 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 01:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 6,348 | $32.32 | $205,143.24 |
DisclosureSEC source: 0001672659-26-000004 · wk-form4_1768355008.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,804 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.01 to $32.93. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 01:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001672659-26-000004 · wk-form4_1768355008.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 01:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 2,170 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001672659-26-000004 · wk-form4_1768355008.xml · derivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,218 Underlying: Common Stock · 2,170 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 01:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 2,170 | $33.27 | $72,195.90 |
DisclosureSEC source: 0001672659-26-000004 · wk-form4_1768355008.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,804 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 01:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 2,170 | $16.00 | $34,720.00 |
DisclosureSEC source: 0001672659-26-000004 · wk-form4_1768355008.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 67,473 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 23 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,334 Underlying: Common Stock · 67,473 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 53,630 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 22 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,388 Underlying: Common Stock · 53,630 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 26,069 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 21 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,584 Underlying: Common Stock · 26,069 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F7 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 10,121 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 20 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 10,121 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 28,038 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 19 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,440 Underlying: Common Stock · 28,038 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 53,470 | $35.53 | $1,899,553.83 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 13 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,804 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.2100 to $35.7700. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 139,245 | $34.83 | $4,849,555.24 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 12 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,274 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.2100 to $35.2021. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 67,473 | $14.25 | $961,490.25 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 11 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 254,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 53,630 | $16.00 | $858,080.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 10 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 26,069 | $10.20 | $265,903.80 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 9 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 10,121 | $15.44 | $156,268.24 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 8 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 28,038 | $1.08 | $30,281.04 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 7 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 24,193 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 18 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,807 Underlying: Common Stock · 24,193 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 20,168 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 17 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,018 Underlying: Common Stock · 20,168 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 9,347 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 16 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,653 Underlying: Common Stock · 9,347 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F7 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 3,629 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 15 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,371 Underlying: Common Stock · 3,629 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 10,053 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · derivative · entry 14 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,478 Underlying: Common Stock · 10,053 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 70,037 | $35.87 | $2,511,919.03 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,188 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.6550 to $36.4522. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 24,193 | $14.25 | $344,750.25 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 20,168 | $16.00 | $322,688.00 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 9,347 | $10.20 | $95,339.40 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 3,629 | $15.44 | $56,031.76 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 10,053 | $1.08 | $10,857.24 |
DisclosureSEC source: 0001672659-26-000002 · wk-form4_1767745246.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · balance_after: This balance includes 680 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 23:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,369 | $43.01 | $445,982.10 |
DisclosureSEC source: 0001933414-25-000128 · wk-form4_1760569464.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,155 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.8000 to $43.1950. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 22:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 2,065 | $36.47 | $75,320.46 |
DisclosureSEC source: 0001672659-25-000006 · wk-form4_1758063276.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,524 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.4026 to $36.7005. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 22:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 9,302 | $35.90 | $333,945.52 |
DisclosureSEC source: 0001672659-25-000006 · wk-form4_1758063276.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,589 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.4000 to $36.3955. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 22:02 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 11,365 | $12.93 | $146,986.95 |
DisclosureSEC source: 0001933414-25-000093 · wk-form4_1755208973.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,891 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.590 to $13.223. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:02 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000093 · wk-form4_1755208973.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,531 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on July 12, 2022, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:02 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-25-000093 · wk-form4_1755208973.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. Read SEC document |
| July 14, 2025 Filed Jul 15, 2025 21:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000076 · wk-form4_1752613231.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,880 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 14, 2025 Filed Jul 15, 2025 21:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 11,366 | $14.59 | $165,878.81 |
DisclosureSEC source: 0001933414-25-000076 · wk-form4_1752613231.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,907 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.0700 to $14.7594. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| July 14, 2025 Filed Jul 15, 2025 21:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-25-000076 · wk-form4_1752613231.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · balance_after: This balance includes 1,273 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:03 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 11,366 | $14.60 | $165,931.10 |
DisclosureSEC source: 0001933414-25-000067 · wk-form4_1750104191.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,651 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.370 to $14.835. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:03 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000067 · wk-form4_1750104191.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,229 Underlying: Common Stock · 6,348 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:03 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001933414-25-000067 · wk-form4_1750104191.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. Read SEC document |
| May 14, 2025 Filed May 15, 2025 23:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 11,366 | $15.29 | $173,773.64 |
DisclosureSEC source: 0001933414-25-000062 · wk-form4_1747350094.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,669 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.9100 to $15.7726. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 12, 2025 Filed May 14, 2025 00:57 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000060 · wk-form4_1747184222.xml · derivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,577 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 12, 2025 Filed May 14, 2025 00:57 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-25-000060 · wk-form4_1747184222.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 00:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000047 · wk-form4_1744763954.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,926 Underlying: Common Stock · 6,348 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 00:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 8,400 | $14.83 | $124,572.00 |
DisclosureSEC source: 0001933414-25-000047 · wk-form4_1744763954.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,686 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 00:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 2,966 | $13.69 | $40,613.14 |
DisclosureSEC source: 0001933414-25-000047 · wk-form4_1744763954.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,086 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.5382 to $13.8250. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.